Key indicators – Q1 2025:

• Turnover increased by 33% compared to Q1 2024 
• EBITDA reached RON 40.5 million, up by 51% 
• Net profit rose by approximately 57% compared to the same period last year 

Bucharest, May 14, 2025 – Biofarm (stock symbol BIO), one of the largest pharmaceutical producers in Romania, recorded a 33% increase in turnover compared to Q1 2024. EBITDA grew by 51%, reaching RON 40.5 million, while net profit rose by approximately 57%. These results reflect the efficiency of the company’s operational model and the improved commercial performance. 

 „The results achieved in the first three months of this year confirm the effectiveness of our development strategy, despite a complex economic context influenced by rising raw material and packaging prices. We continue to invest in portfolio expansion and process optimization, while maintaining our strategic direction focused on innovation and sustainable growth,” said Cătălin Vicol, CEO of Biofarm.

In the first quarter, Biofarm maintained its position as the second-largest player in the Consumer Healthcare (CHC) segment in terms of units sold. Sales were supported by strong performance in categories addressing cold and flu symptom relief, digestive health, pain management, and emotional balance. The company holds the leading volume position in six key categories through its brands: Bixtonim, Colebil, Triferment, Extravalerianic, Carmol și Carbocit. 
 
Biofarm remains committed to research and development, considering it a key pillar of its long-term growth strategy. Ongoing investments in portfolio innovation and the development of relevant therapeutic solutions are essential to addressing current patient needs and strengthening the company’s position in the Romanian pharmaceutical industry. 
 
Biofarm operates two pharmaceutical production facilities in Bucharest and a dedicated testing and product development unit. Its portfolio of over 100 products covers key therapeutic areas within the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, and nervous system).  

 

About Biofarm 

Biofarm® is one of the first Romanian drug and food supplements producers. For 100 years, Biofarm® has stood alongside Romanian specialists in the race to discover the best solutions for maintaining people's health. Biofarm® is currently one of the top 10 existing producers on the pharmaceutical market in Romania, a very dynamic and competitive market. Biofarm® has a competitive product portfolio, covering 65 therapeutic areas, and is continuously investing in media, commercial and marketing campaigns to promote its products.